MX2023001255A - Terapia de combinación para el tratamiento del cáncer. - Google Patents

Terapia de combinación para el tratamiento del cáncer.

Info

Publication number
MX2023001255A
MX2023001255A MX2023001255A MX2023001255A MX2023001255A MX 2023001255 A MX2023001255 A MX 2023001255A MX 2023001255 A MX2023001255 A MX 2023001255A MX 2023001255 A MX2023001255 A MX 2023001255A MX 2023001255 A MX2023001255 A MX 2023001255A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
combination therapy
administration
methods
Prior art date
Application number
MX2023001255A
Other languages
English (en)
Inventor
Christopher G Twitty
Original Assignee
Oncosec Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Inc filed Critical Oncosec Medical Inc
Publication of MX2023001255A publication Critical patent/MX2023001255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Se describen métodos y pautas posológicas para tratar cáncer con electroporación intratumoral de una citocina inmunoestimuladora combinada con la administración de un inhibidor de puntos de control inmunitarios y un agente quimioterapéutico.
MX2023001255A 2020-07-29 2021-07-29 Terapia de combinación para el tratamiento del cáncer. MX2023001255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063058026P 2020-07-29 2020-07-29
PCT/US2021/043665 WO2022026682A1 (en) 2020-07-29 2021-07-29 Combination therapy for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023001255A true MX2023001255A (es) 2023-05-15

Family

ID=80036752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001255A MX2023001255A (es) 2020-07-29 2021-07-29 Terapia de combinación para el tratamiento del cáncer.

Country Status (10)

Country Link
US (1) US20230302090A1 (es)
EP (1) EP4188524A1 (es)
JP (1) JP2023536460A (es)
KR (1) KR20230042350A (es)
AU (1) AU2021319075A1 (es)
BR (1) BR112023001514A2 (es)
CA (1) CA3187206A1 (es)
IL (1) IL300106A (es)
MX (1) MX2023001255A (es)
WO (1) WO2022026682A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098615A1 (en) * 2018-05-02 2019-11-07 Oncosec Medical Incorporated Electroporation systems, methods, and apparatus

Also Published As

Publication number Publication date
AU2021319075A1 (en) 2023-03-09
CA3187206A1 (en) 2022-02-03
IL300106A (en) 2023-03-01
US20230302090A1 (en) 2023-09-28
JP2023536460A (ja) 2023-08-25
KR20230042350A (ko) 2023-03-28
EP4188524A1 (en) 2023-06-07
WO2022026682A1 (en) 2022-02-03
BR112023001514A2 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2021008418A (es) Terapias de farmaco de combinacion de inhibidores de fosfodiesterasa tipo 5 (pde-5) y oxido nitrico inhalado.
MX2021000726A (es) Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
MX2020001727A (es) Terapia de combinacion.
MX2022004577A (es) Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
AR121691A1 (es) Composiciones de rna dirigidas a claudina-18.2
IL290123A (en) Combined treatment including antibodies against claudin 18.2 and immune checkpoint inhibitors for cancer treatment
MX2023004029A (es) Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX2023012515A (es) Tratamiento del cancer con un inhibidor de raf.
MX2023001255A (es) Terapia de combinación para el tratamiento del cáncer.
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2019001545A (es) Composiciones y metodos para tratar cancer con supresion de arginina y agentes de inmuno-oncologia.
WO2022174064A3 (en) Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
MX2023006404A (es) Terapia combinada de anticuerpos y taxanos.
WO2023009834A3 (en) Methods of treating cancer
MX2022009270A (es) Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer.
JOP20220073A1 (ar) استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية
MX2023005234A (es) Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.